Annie Tang1, Caitlin M Cohan2, Keith S Hansen2, Genna Beattie2, Heather I Greenwood3, Rita A Mukhtar2. 1. Department of Surgery, University of California, San Francisco, 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94158, USA. annie.tang@ucsf.edu. 2. Department of Surgery, University of California, San Francisco, 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94158, USA. 3. Department of Radiology, University of California San Francisco, San Francisco, CA, USA.
Abstract
PURPOSE: To determine the positive predictive value (PPV) of magnetic resonance imaging (MRI)-guided breast biopsy stratified by body mass index (BMI). Secondary endpoints include evaluation of indications for breast MRI and identification of factors associated with malignant biopsy. METHODS: We retrospectively analyzed results of MRI-guided breast biopsies in a consecutive cohort of women at a single institution between 2014 and 2019. The PPV was compared between BMI subgroups and the overall group by the one-sample z-test. Factors associated with malignant biopsy were analyzed using multivariate regression analysis. RESULTS: Among 427 MRI-guided breast biopsies, the PPV was significantly higher in patients with a BMI ≥ 35 compared to BMI < 35 (38.6% versus 24.5%, p = 0.043). This remained true in the 180 biopsies from high-risk screening studies, but there was no difference in PPV by BMI in the 205 biopsies performed to evaluate extent of known disease. Among this cohort who underwent MRI-guided breast biopsy, the underlying indication for MRI was less likely to be high-risk screening in those with a higher BMI or Black or Hispanic race (p = 0.015 and p < 0.001, respectively). For high-risk screening studies, only BMI ≥ 35 was associated with malignant biopsies (OR 37.5, p = 0.003). For evaluation of extent of disease studies, only increased lesion size was a significant predictor of malignant result (OR 1.01, p = 0.04). CONCLUSIONS: Among women who underwent MRI-guided breast biopsy, elevated BMI was associated with increased PPV and malignant biopsies. Patients with a higher BMI or Black or Hispanic race who had MRI-guided biopsy were less likely to be undergoing high-risk screening and more likely to have breast MRI to evaluate extent of known disease.
PURPOSE: To determine the positive predictive value (PPV) of magnetic resonance imaging (MRI)-guided breast biopsy stratified by body mass index (BMI). Secondary endpoints include evaluation of indications for breast MRI and identification of factors associated with malignant biopsy. METHODS: We retrospectively analyzed results of MRI-guided breast biopsies in a consecutive cohort of women at a single institution between 2014 and 2019. The PPV was compared between BMI subgroups and the overall group by the one-sample z-test. Factors associated with malignant biopsy were analyzed using multivariate regression analysis. RESULTS: Among 427 MRI-guided breast biopsies, the PPV was significantly higher in patients with a BMI ≥ 35 compared to BMI < 35 (38.6% versus 24.5%, p = 0.043). This remained true in the 180 biopsies from high-risk screening studies, but there was no difference in PPV by BMI in the 205 biopsies performed to evaluate extent of known disease. Among this cohort who underwent MRI-guided breast biopsy, the underlying indication for MRI was less likely to be high-risk screening in those with a higher BMI or Black or Hispanic race (p = 0.015 and p < 0.001, respectively). For high-risk screening studies, only BMI ≥ 35 was associated with malignant biopsies (OR 37.5, p = 0.003). For evaluation of extent of disease studies, only increased lesion size was a significant predictor of malignant result (OR 1.01, p = 0.04). CONCLUSIONS: Among women who underwent MRI-guided breast biopsy, elevated BMI was associated with increased PPV and malignant biopsies. Patients with a higher BMI or Black or Hispanic race who had MRI-guided biopsy were less likely to be undergoing high-risk screening and more likely to have breast MRI to evaluate extent of known disease.
Authors: Debbie Saslow; Carla Boetes; Wylie Burke; Steven Harms; Martin O Leach; Constance D Lehman; Elizabeth Morris; Etta Pisano; Mitchell Schnall; Stephen Sener; Robert A Smith; Ellen Warner; Martin Yaffe; Kimberly S Andrews; Christy A Russell Journal: CA Cancer J Clin Date: 2007 Mar-Apr Impact factor: 508.702
Authors: Marian L Neuhouser; Aaron K Aragaki; Ross L Prentice; JoAnn E Manson; Rowan Chlebowski; Cara L Carty; Heather M Ochs-Balcom; Cynthia A Thomson; Bette J Caan; Lesley F Tinker; Rachel Peragallo Urrutia; Jennifer Knudtson; Garnet L Anderson Journal: JAMA Oncol Date: 2015-08 Impact factor: 31.777
Authors: Emily Banks; Gillian Reeves; Valerie Beral; Diana Bull; Barbara Crossley; Moya Simmonds; Elizabeth Hilton; Stephen Bailey; Nigel Barrett; Peter Briers; Ruth English; Alan Jackson; Elizabeth Kutt; Janet Lavelle; Linda Rockall; Matthew G Wallis; Mary Wilson; Julietta Patnick Journal: BMJ Date: 2004-08-28
Authors: Joann G Elmore; Patricia A Carney; Linn A Abraham; William E Barlow; Joseph R Egger; Jessica S Fosse; Gary R Cutter; R Edward Hendrick; Carl J D'Orsi; Prashni Paliwal; Stephen H Taplin Journal: Arch Intern Med Date: 2004-05-24
Authors: Jae Won Park; Kyungdo Han; Dong Wook Shin; Yohwan Yeo; Ji Won Chang; Jung Eun Yoo; Su-Min Jeong; Se-Kyung Lee; Jai Min Ryu; Yong-Moon Park Journal: Breast Cancer Res Treat Date: 2020-10-03 Impact factor: 4.872
Authors: Piet A van den Brandt; Regina G Ziegler; Molin Wang; Tao Hou; Ruifeng Li; Hans-Olov Adami; Claudia Agnoli; Leslie Bernstein; Julie E Buring; Yu Chen; Avonne E Connor; A Heather Eliassen; Jeanine M Genkinger; Gretchen Gierach; Graham G Giles; Gary G Goodman; Niclas Håkansson; Vittorio Krogh; Loic Le Marchand; I-Min Lee; Linda M Liao; M Elena Martinez; Anthony B Miller; Roger L Milne; Marian L Neuhouser; Alpa V Patel; Anna Prizment; Kim Robien; Thomas E Rohan; Norie Sawada; Leo J Schouten; Rashmi Sinha; Rachael Z Stolzenberg-Solomon; Lauren R Teras; Shoichiro Tsugane; Kala Visvanathan; Elisabete Weiderpass; Kami K White; Walter C Willett; Alicja Wolk; Anne Zeleniuch-Jacquotte; Stephanie A Smith-Warner Journal: Eur J Epidemiol Date: 2020-10-30 Impact factor: 12.434